AVEO Oncology Launches Phase 1b/2 Clinical Trial for AML
AVEO Oncology, an LG Chem company, has taken a significant step in the fight against acute myeloid leukemia (AML) by successfully dosing the first patient in a Phase 1b/2 clinical trial of their investigational drug, ficlatuzumab. The trial is an innovative collaboration with Blood Cancer United to assess the efficacy of ficlatuzumab in combination with azacitidine and venetoclax, specifically targeting older patients who are 60 years and above and have untreated AML.
Collaborative Efforts in Clinical Research
This strategic partnership with Blood Cancer United, a prominent nonprofit dedicated to blood cancer research and advocacy, underscores the importance of cooperative efforts in clinical trials. The Beat AML Master Clinical Trial is notable as the first collaborative precision medicine trial in blood cancers, aiming to explore various therapies within a unified framework.
Blood Cancer United sponsors the trial as a sub-study of the Beat AML initiative, which employs advanced methodologies to evaluate multiple treatment protocols, enhancing the potential to better match therapies to patients' specific genetic profiles.
Details of the Clinical Trial
The Phase 1b/2 trial aims to establish the safety, pharmacokinetics, and preliminary efficacy of the ficlatuzumab combination therapy. Ficlatuzumab functions as a humanized IgG1 monoclonal antibody that inhibits the hepatocyte growth factor (HGF) from binding to its receptor, c-Met. This mechanism is critical, especially in AML, where signaling pathways can lead to cancer cell growth and survival.
Previous early-phase studies have shown positive results for ficlatuzumab when used alongside cytarabine in AML, revealing a favorable safety profile and beneficial clinical activity. Such findings support the rationale for investigating ficlatuzumab further in a population lacking suitable treatment options and considered unfit for standard therapies.
Leadership Perspectives on the Collaboration
Michael P. Bailey, the President and CEO of AVEO, expressed his enthusiasm: "This collaboration marks a pivotal advancement for both AVEO and Blood Cancer United. We are committed to enhancing patient outcomes through innovative clinical research, and this partnership amplifies our efforts in addressing significant unmet medical needs with our developmental therapies."
Moreover, Lore Gruenbaum, Ph.D., Chief Scientific Officer at Blood Cancer United, stated, "This trial aims to revolutionize how we treat AML, adopting an innovative precision medicine strategy. Our alliance with AVEO is crucial for the progress and effectiveness of this significant clinical trial, working towards improving patient care for adults with this formidable cancer."
About AVEO Oncology
AVEO Pharmaceuticals, Inc., under the umbrella of LG Chem, focuses on developing groundbreaking medications aimed at providing enhanced life quality for cancer patients. The company currently markets FOTIVDA (tivozanib) for advanced renal cell carcinoma in the United States, following preceding systemic therapies.
Additionally, AVEO is exploring other critical areas such as ficlatuzumab for HPV-negative refractory head and neck cancer and rilogrotug in managing cancer cachexia. Recently, AVEO transitioned to a wholly-owned subsidiary of LG Chem Life Sciences USA, furthering its mission under the AVEO Oncology brand.
About LG Chem
LG Chem represents a leading global chemical entity with a diverse portfolio ranging from petrochemicals to life sciences. Their Life Sciences division actively works on the development of innovative therapies across numerous health sectors. Guided by their foundational goal of transforming lives through scientific advancement, LG Chem Life Sciences strives to offer pioneering solutions that meet customer needs.
About Blood Cancer United
Previously known as the Leukemia & Lymphoma Society, Blood Cancer United stands as the largest global organization committed to blood cancer support and research. Their mission is to eradicate blood cancer while enhancing life quality for patients and their families. Through collaboration and community engagement, they aim to ensure that all blood cancer patients experience longer, richer lives.
About Ficlatuzumab
Ficlatuzumab, recognized for its strong inhibitory action against hepatocyte growth factor, is currently undergoing multiple trials due to its potential in treating various cancers. The U.S. FDA has recognized its development as a Fast Track initiative for specific cancers, showcasing its importance in contemporary oncological treatment paradigms.
Frequently Asked Questions
What is the main objective of the Phase 1b/2 trial?
The trial aims to evaluate the safety and efficacy of ficlatuzumab in combination with other drugs for treating acute myeloid leukemia.
Who is sponsoring the clinical trial?
Blood Cancer United is sponsoring the trial as part of their Beat AML initiative.
What is ficlatuzumab?
Ficlatuzumab is an investigational monoclonal antibody that inhibits signaling through the c-Met receptor, potentially affecting cancer growth.
Who are the participants in the trial?
The trial focuses on patients aged 60 and above with untreated acute myeloid leukemia.
What is AVEO's role in this collaboration?
AVEO is spearheading the clinical trial, focused on improving outcomes for blood cancer patients with their innovative therapies.
